All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. IGF-1 LR3 (Long R3 IGF-1) is an engineered analog of insulin-like growth factor 1 that researchers study in cell-culture and preclinical models of growth signaling and cellular proliferation.
What IGF-1 LR3 Is
IGF-1 LR3 is a recombinant, structurally modified version of native insulin-like growth factor 1. Two changes define it: an arginine substitution at position 3 and an additional 13-amino-acid N-terminal extension. In published research these modifications are described as substantially reducing the molecule’s affinity for IGF-binding proteins (IGFBPs) while preserving binding to the type 1 IGF receptor. Researchers use it as a laboratory reagent for studying receptor-mediated signaling without the confounding influence of binding-protein sequestration.
Mechanism and What Research Explores
Because the analog has very low affinity for IGFBPs but retains the ability to bind the type 1 IGF receptor, studies have examined it as a tool for probing IGF receptor activation and downstream proliferation pathways in cultured cells. Researchers study its use in myogenic cell models to dissect IGF-dependent versus IGF-independent effects of binding proteins, and it has been used as a stable IGF-1 analog in preclinical vascular models. The research interest centers on how sustained receptor engagement influences cell proliferation, differentiation, and survival signaling under controlled in vitro conditions.
Research Stage and Limitations
The available literature on IGF-1 LR3 is largely confined to in vitro cell-culture systems and animal models. Findings from such systems do not translate directly to any human or veterinary context, and the compound is not approved for use in either. Reported effects vary by cell type, assay conditions, and binding-protein environment, which limits broad generalization. Any community or anecdotal mention of IGF-1 LR3 outside controlled research settings should be treated as unverified anecdotal reports, not controlled findings, and BioRegen does not make or endorse any claims based on them.
Laboratory Handling Notes
Like many lyophilized research peptides and proteins, IGF-1 LR3 is typically supplied as a freeze-dried powder that researchers reconstitute with an appropriate solvent before bench work. General laboratory practice emphasizes minimizing freeze-thaw cycles, keeping reconstituted material cold, and recording lot and storage details for reproducibility. For general reconstitution background in a research context, see our guide on how to reconstitute peptides. Researchers comparing growth-research compounds may also find the growth research category useful for surveying available reference materials.
Is IGF-1 LR3 the same as native IGF-1?
No. In research literature it is described as an engineered analog with an arginine-3 substitution and an N-terminal extension, which lower its affinity for IGF-binding proteins compared with the native molecule while preserving receptor binding.
Why do researchers use the LR3 form in cell culture?
Studies have used it because its low binding-protein affinity allows investigators to probe type 1 IGF receptor signaling with reduced interference from IGFBPs present in culture media.
How does it compare to other growth-research compounds?
Comparisons depend entirely on the research question and model. To survey and compare reference compounds, researchers can use our research finder.
For Research Teams
For background on sourcing and documenting laboratory reference materials, see the BioRegen research guide, and use code RESEARCH10 for 10% off your first order. You can also browse the growth research category to compare available reference compounds.
Selected research references
- von der Thüsen JH, et al. IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. Am J Pathol. 2011. https://doi.org/10.1016/j.ajpath.2010.10.007
- Xi G, et al. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. J Cell Physiol. 2004. https://doi.org/10.1002/jcp.20068
Reference metadata sourced via PubMed.
This article is provided for laboratory and educational research purposes only. No compound referenced is approved for human or veterinary use, and nothing here constitutes medical advice or a recommendation for use in humans or animals. BioRegen does not make therapeutic claims.
